AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01398319 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Bystander Intervention
Description: The 1-hour Bystander intervention was a non-alcohol related briefing that served as the control condition. The intervention focused on increasing Airmen's awareness of the qualities of being a good wingman (e.g., watching for their peers) and how those are tied to the Air Force Core Values. It aimed to increase participants' perceived responsibility to act in certain situations. The intervention draws on the philosophy that members in a community have a role in shifting social norms to prevent violence (Coker et al., 2011). While the intervention did not directly discuss alcohol use, the focus on military values and taking responsibility for one's self and others could contribute to healthier drinking-related choices.
Study NCT02845622 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hazelnut
Description: This dietary supplement contains 30 g of hazelnut.
Study NCT02845622 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cocoa
Description: This dietary supplement contains 2.5 g of cocoa powder.
Study NCT02845622 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: No hazelnuts / No cocoa
Description: This dietary supplement does not contain hazelnut nor cocoa powder.
Study NCT02845622 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cream
Description: This dietary supplement is just a cream obtained by grinding hazelnuts.
Study NCT02845622 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Snack
Description: This dietary supplement is a commercial snack containing either hazelnut or cocoa or both.
Study NCT02845622 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Snack
Description: This dietary supplement is a commercial snack containing either hazelnut or cocoa or both.
Study NCT02715024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Description: Oral
Study NCT02715024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin
Description: Oral
Study NCT04251767 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: washed microbiota transplantation
Description: Washed microbiota suspension (5u) delivered through nasogastric tube, nasojejunal tube or oral.~Dose and frequency: 5u, once.
Study NCT04251767 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo (edible suspension of the same color as the washed microbiota suspension，5u) administered via nasogastric tube, nasojejunal tube or oral, combining with standard therapy.~Dose and frequency: 5u, once.
Study NCT03155919 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TAUchoc
Description: The supplements were offered during eight weeks in capsules containing three grams of taurine powder and 400 ml of chocolate milk ready to drink.
Study NCT03155919 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PLAchoc
Description: The supplements were offered during eight weeks in capsules containing three grams of placebo (starch powder) and 400 ml of chocolate milk ready to drink.
Study NCT01952548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-312
Study NCT01952548 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03576066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-H0731
Description: Participants will receive ABI-H0731 300 mg tablets orally once daily (QD).
Study NCT03576066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOC NUC
Description: Participants will continue on their SOC NUC (ETV, TDF or TAF) tablet orally as per approved package insert.
Study NCT01571427 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active social engagement group
Description: Engage in 30 minutes conversation daily using internet/webcam, 5 days per week for 6 weeks, tracking of daily conversational amount outside of the trial by using a digital recording device, lasting effects will be assessed at the 3rd and 6th month after completion of the intervention
Study NCT01571427 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: No active intervention, weekly phone calls by interviewer to complete health/social engagement monitoring survey, tracking of daily conversational amount by using a digital recording device. Participants will be reassessed at the 3rd and 6th month after completion of the intervention.
Study NCT01030939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-649868
Description: In each of all cohorts, 18 subjects will be randomised in a 2:1 ratio to receive either SB-649868 or placebo
Study NCT02338414 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Romiplostim
Description: Subcutaneous Romiplostim (weekly injection) -> if titrated with maintaining PLT count between 50-200 x 10\^9/L -> Subcutaneous Romiplostim (biweekly injection)
Study NCT03837106 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation program
Description: 3-month rehabilitation program comprising exercise and education specific to musicians. The program will be supported by an online platform containing more than 50 exercise videos, narrated powerpoint presentations, informative videos, quizzes, and forums for communicating with a physiotherapist and for organizing group exercise sessions.
Study NCT05782465 — intervention group
Intervention type: PROCEDURE
Intervention: Blood Collection, processing and analyses
Description: 20ml of blood will be drawn from study participant at the baseline visit for molecular analyses.
Study NCT05782465 — intervention group
Intervention type: PROCEDURE
Intervention: Gastroscopy and biopsies collection
Description: Study participant will undergo gastroscopy with collection of gastric mucosal biopsies at the baseline visit to ascertain OLGIM status and for molecular analyses. Study participant will undergo surveillance gastroscopy for gastric cancer at years 2 and 4 to assess whether they have reached endpoint.
Study NCT05782465 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Urea Breath Test
Description: Study participant will fast for 6 hours or overnight before undergoing the Urea Breath Test (UBT) to test for current H. pylori infection. Breath collection will be performed before ingestion of 13C urea, and at specified time intervals after ingestion.
Study NCT05012839 — intervention group
Intervention type: OTHER
Intervention: impact of COVID-19 on Health-Seeking Behaviors
Description: The impact of the coronavirus disease 2019 (COVID-19) pandemic on medical services is overwhelming due to limited medical resources. During its initial surge in 2020, Taiwan's government rapidly established diverse public actions, which helped maintain the medical supply without travel restrictions. However, whether the fear of being infected with COVID-19 interfered with health-seeking behavior (HSB) remains unclear. Therefore, this study aimed to elucidate whether acute complicated appendicitis (ACA) rates in adults were affected by the COVID-19 pandemic.
Study NCT01923701 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: GF-CBT focuses on teaching emotional self-regulation, information processing, decision making strategies,and logical thinking skills. The program is comprised of three parts: 1) Group sessions in which adolescents receive social support from peers who have had similar experiences and learn CBT skills, 2) Family group sessions in which family members learn more about adolescents' experiences and learn CBT skills so that they can encourage and reinforce these skills at home, and 3) Individual sessions in which adolescents can apply CBT skills to their own lives and work toward personal goals. Group sessions are taught with Powerpoint slides and with an accompanying workbook.
Study NCT01176669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib was administratered at 750 mg/d in Phase IIa. The actual average dose intensity delivered was 525 mg/d due to toxicities. So, in Phase IIb, the starting dose of apatinib will be 500mg/d. Two dose reductions will be allowed to 375 and then 250 mg/d.
Study NCT00053053 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Juven
Study NCT00053053 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Non-Juven Supplement
Study NCT01282268 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: arbaclofen
Description: orally disintegrating tablet
Study NCT01282268 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: orally disintegrating tablet
Study NCT01516320 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Roux-en-Y Gastric Bypass
Description: A surgical technique in which the stomach is stapled into a smaller pouch and then attached directly to the small intestine, bypassing the rest of the original stomach. The goal of the surgery is weight loss.
Study NCT01516320 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic adjustable gastric banding
Description: A surgical technique in which an inflatable silicone device placed around the top portion of the stomach, creating a smaller gastric pouch. The goal of the surgery is weight loss.
Study NCT01516320 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vertical Sleeve Gastrectomy
Description: A surgical technique in which a large portion of the stomach is removed, leaving only a smaller gastric pouch. The goal of the surgery is weight loss.
Study NCT03991715 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Activity Tracker
Description: Individually tailored daily and weekly physical activity goals established for all participants. Participants sent weekly reports for 6 weeks after cardiac rehabilitation discharge.
Study NCT02839707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV
Study NCT02839707 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study NCT02839707 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Given IV
Study NCT02839707 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT02839707 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT
Study NCT02839707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicin Hydrochloride
Description: Given IV
Study NCT02839707 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated Liposomal Doxorubicin Hydrochloride
Description: Given IV
Study NCT02839707 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02839707 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT01832376 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound guided needle lavage
Description: A 18-gauge needle connected to a 5 ml syringe with 4 ml of saline solution will be used to puncture the calcification with freehand technique and under constant sonographic monitoring. With the tip of the needle placed in the center of the deposit, the calcification will be flushed. If backflow of calcific material can be identified in the syringe, lavage of the deposit will be performed by successive propulsion and aspiration with the syringe plunger. In cases where no material can be extracted, repeated perforation of the deposit will be performed to possibly initiate or accelerate spontaneous resorption.
Study NCT00060112 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: oblimersen sodium
Description: Given IV
Study NCT00060112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study NCT00060112 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00060112 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02989675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10% dextrose
Description: Bolus of 10% dextrose 5mls/kg
Study NCT03413566 — intervention group
Intervention type: OTHER
Intervention: Clinical diagnosis
Description: A clinical diagnosis of cerebral palsy given by a pediatrician at a habilitation center in Norway.
Study NCT02480842 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alloplastic free ROM
Study NCT02480842 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alloplastic limited ROM
Study NCT02480842 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oncoplastic free ROM
Study NCT02480842 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oncoplastic limited ROM
Study NCT03535103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonal-F®
Description: A single Subcutaneous injection, 225IU
Study NCT03535103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LM001
Description: A single Subcutaneous injection, 225IU
Study NCT02880189 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Orbera Intragastric Balloon
Description: The Orbera Intragastric Balloon will be placed in the stomach endoscopically through a catheter under conscious sedation. The procedure takes about 20 minutes to complete. The balloon will stay in place for 6 months and then it will be removed endoscopically.
Study NCT02880189 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endoscopic Ultrasound Guided Core Liver Biopsy
Study NCT03576066 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SOC NUC
Description: Participants will continue on their SOC NUC (ETV, TDF or TAF) tablet orally as per approved package insert.
Study NCT03576066 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Participants will receive placebo matching ABI-0731 tablets orally QD.
Study NCT03521232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niclosamide
Description: enema given twice daily for 6 weeks
Study NCT01474772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: 150-300 mg/day given in 3 divided doses as capsules
Study NCT01474772 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo capsules given in 3 divided doses
Study NCT01131429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib 150 mg/d per os until proven disease progression
Study NCT01131429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75mg/m2 iv day 1 every 3 weeks as second-line treatment
Study NCT02289898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Demcizumab
Description: administered intravenously
Study NCT01131429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: cisplatin 75mg/ m2 iv day 1 every 3 weeks as second-line treatment
Study NCT01131429 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel 75mg/m2 iv day 1 every 3 weeks for 6 cycles at most
Study NCT01131429 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 75mg/m2 iv day 1 every 3 weeks for 6 cycles at most
Study NCT01131429 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib
Description: Erlotinib 150 mg/d per os as second-line treatment
Study NCT04131205 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging
Description: We will assess the role of magnetic resonance (MR) in mHE diagnosis with emphasis on multimodal imaging technique
Study NCT01991080 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: biofeedback
Description: Patients will go through biofeedback sessions
Study NCT01991080 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Wheatgerm juice
Description: Patient will drink wheatgerm juice
Study NCT03374267 — intervention group
Intervention type: OTHER
Intervention: Routine care as per site standard.
Description: Physician's choice according to patient's needs.
Study NCT01619059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin IR
Description: Tablets, Oral, ≥ 1500mg, Twice daily, Up to 52 weeks
Study NCT01619059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching with Saxagliptin
Description: Tablets, Oral, 0 mg, Once daily, Up to 52 weeks
Study NCT05430087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Observe the clinical outcome and inflammatory cytokines levels in patients with systemic lupus erythematosus (SLE) after being supplemented with Cholecalciferol (Vitamin D3) and Curcumin-Piperine.
Description: All patients and physicians were blinded to group assignment and treatment allocation. All subjects received the tablets for three months. All subjects were still required to consume their routine medications during the supplementation according to the disease activity. Patients were evaluated at baseline and after the end of supplementation for clinical and laboratory parameters. Adherence to therapy was assessed by monthly pill counts of returned tablets and biweekly phone calls to the patients.
Study NCT01444625 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flavanol-rich chocolate
Description: High-flavanol chocolate, 12 weeks.
Study NCT01444625 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Flavanol-free chocolate
Description: Flavanol-free chocolate, 12 weeks
Study NCT04549779 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low volume interscalene brachial plexus block
Description: ultrasound-guided interscalene brachial plexus block with 5 ml levobupivacaine 0.25%
Study NCT04549779 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intermediate volume interscalene brachial plexus block
Description: ultrasound-guided interscalene brachial plexus block with 10 ml levobupivacaine 0.25%
Study NCT04549779 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High volume interscalene brachial plexus block
Description: ultrasound-guided interscalene brachial plexus block with 15 ml levobupivacaine 0.25%
Study NCT01414023 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Control Training
Description: Pace Auditory Serial Addition Task (PASAT;(Gronwall, 1977): A computer version of the PASAT will be used to measure sustained attention and working memory. Participants are asked to add serially presented numbers. Attention Control Intervention (Wells, 2000): This task involves training individuals to attend differentially to multiple auditory sources (e.g., by counting tones, discriminating the location of tones, and moving their attention between auditory sources for a prolonged period).
Study NCT01414023 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Peripheral Vision Task
Description: Peripheral Vision Task (PVT; C. Moore, personal communication): This task serves as a non-active control condition which does not target the brain regions influenced by the Wells and PASAT tasks. Participants focus on the placement of dots on a computer screen in this task while listening to a tone.
Study NCT01552551 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Assessment and education
Description: PA Healthy Steps program
Study NCT01552551 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Steps with Falls Case Management
Description: Counseling to ensure that participants receive a physician assessment and home safety check
Study NCT01552551 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Steps in Motion
Description: Group exercise program
Study NCT01497990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertapenem
Description: The patient received two injections of ertapenem, at a dose of 1g.j-1 by intravenous injection of 30 minutes, separated by 24 h.
Study NCT03692377 — intervention group
Intervention type: DEVICE
Intervention: Virtual Reality
Description: Stage 1 : Demonstration of the use of the VR headset by the research assistant (anticipated 1-2 min) Stage 2 : Child will choose the application they would like to see - they will be shown 3 pages of the three applications offered - see Fig 1 (anticipated 1-2 min) Stage 3 : Handling of the VR headset by the child (anticipated 1 min) Stage 4 : Applying the headset on the eyes of the child with software application (anticipated 1 min) Stage 5 : The child use the VR set and application (up to 10 minutes) Stage 6 : Removal of the headset (anticipated 1 min) Stage 7 : Questionnaire to child (interview - 2 minutes) Stage 8 : Questionnaire to parents/guardians (interview - 2 minutes)
Study NCT02498886 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: IHAT
Description: Iron hydroxide adipate tartrate (IHAT): Single dose capsule containing IHAT equivalent to 60mg iron with 2 mg isotopically enriched with 58Fe.
Study NCT02498886 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ferrous sulphate
Description: Ferrous sulphate: Single dose capsule containing ferrous sulphate heptahydrate equivalent to 60 mg iron with 10 mg isotopically enriched with 57Fe.
Study NCT02289898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane®
Description: administered intravenously
Study NCT02289898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: administered intravenously